ADDF's 11th International Conference on Alzheimer's Drug Discovery

PROGRAM

All sessions will be held at the Hyatt Regency Jersey City.

Sunday, September 26
5:00–7:00 pm	On-Site Pre-Registration
Monday, September 27
8:00 – 8:30am	Registration & Continental Breakfast
8:30 – 8:40	Welcome & Opening Remarks
8:30 – 8:40	Howard Fillit, MD, Alzheimer's Drug Discovery Foundation
8:40 – 9:15	Plenary: Progression of Alzheimer’s from Normal to Dementia; Findings from the Alzheimer’s Disease Neuroimaging Initiative
8:40 – 9:15	Holly Soares, PhD, Bristol-Myers Squibb
I. Biomarkers to Accelerate Drug Discovery - Chair: TBA
9:15 – 9:20	Session Overview – TBA
9:20 – 9:40	Predictive Imaging for the Diagnosis of Dementia
9:20 – 9:40	Dawn Matthews, MS, MBA, Abiant, Inc.
9:40 – 9:50	Q&A
9:50 – 10:10	Metabolic Signatures of Preclinical and Early Alzheimer’s Disease
9:50 – 10:10	Rima Kaddurah-Daouk, PhD, Duke University Medical Center
10:10 – 10:20	Q&A
10:20 – 10:50	BREAK / VIEW POSTERS
10:50 – 11:10	Frontotemporal Lobar Degeneration (FTLD) Biomarker Assays
10:50 – 11:10	Linda Kwong, PhD, University of Pennsylvania School of Medicine
11:10 – 11:20	Q&A
11:20 – 11:40	Immunosignatures: A Simple Method to Potentially Diagnose Alzheimer’s Disease
11:20 – 11:40	Stephen Johnston, PhD, Arizona State University Foundation
11:40 – 11:50	Q&A
11:50 – 12:10	Combined CSF Biomarkers and Genotype for Diagnosis of Lewy Body Dementia (LBD)
11:50 – 12:10	Lawrence S. Honig, MD, PhD, Columbia University
12:10 – 12:20	Q&A
12:20 – 1:30	LUNCH / VIEW POSTERS
II. Targeting Beta-Amyloid Production and Clearance - Chair: Sidney Strickland, PhD, The Rockefeller University
1:30 – 1:35	Session Overview – Sidney Strickland, PhD, The Rockefeller University
1:35 – 1:55	Interaction between Abeta and Fibrinogen: A New Therapeutic Target for Alzheimer's Disease
1:35 – 1:55	Sidney Strickland, PhD, The Rockefeller University
1:55 – 2:05	Q&A
2:05 – 2:25	Microvascular Blood Flow Disruptions in the Vicinity of Amyloid Plaques
2:05 – 2:25	Chris Schaffer, PhD, Cornell University
2:25 – 2:35	Q&A
2:35 – 2:55	Development of RAGE Inhibitors for Alzheimer’s Disease
2:35 – 2:55	Rashid Deane, PhD, University of Rochester
2:55 – 3:05	Q&A
3:05 – 3:35	BREAK / VIEW POSTERS
3:35 – 3:55	Screening for Chemical Modifiers of BACE1-Mediated Cleavage of APP
3:35 – 3:55	Tae-Wan Kim, PhD, Columbia University
3:55 – 4:05	Q&A
4:05 – 4:25	The Therapeutic Potential of ABCA1 and ApoE for Alzheimer’s Disease
4:05 – 4:25	Cheryl Wellington, PhD, University of British Columbia Hospital
4:25 – 4:35	Q&A
4:35 – 4:55	Mitochondria-Associated Membranes in Alzheimer’s Disease: A New Target for Drug Discovery
4:35 – 4:55	Eric Schon, PhD, Columbia University
4:55 – 5:05	Q&A
5:05 – 5:10	Closing Remarks
5:05 – 5:10	Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation
5:10 – 7:00	NETWORKING RECEPTION / VIEW POSTERS

Tuesday, September 28
8:00 – 8:30 am	Continental Breakfast
8:30 – 9:05	PLENARY: Stem Cells for Alzheimer’s Disease
8:30 – 9:05	Scott A. Nogle, PhD, The New York Stem Cell Foundation
III. Neuroprotection and Cognitive Enhancement - Chair: Roberta Brinton, PhD, University of Southern California in Los Angeles
9:05 – 9:10	Session Overview – Roberta Brinton, PhD, University of Southern California in Los Angeles
9:10 – 9:30	Allopregnanolone as a Neurogenic Factor for Recovery of Neurons in Alzheimer's Disease
9:10 – 9:30	Roberta Brinton, PhD, University of Southern California in Los Angeles
9:30 – 9:40	Q&A
9:40 – 10:00	Novel PDE5 Inhibitors as a Therapeutic Tool against Alzheimer's Disease
9:40 – 10:00	Ottavio Arancio, MD, PhD, Columbia University
10:00 – 10:10	Q&A
10:10 – 10:30	Development of Klotho Enhancers as Novel Therapeutics for Alzheimer's Disease
10:10 – 10:30	Carmela R. Abraham, PhD, Boston University School of Medicine
10:30 – 10:40	Q&A
10:40 – 11:10	BREAK / VIEW POSTERS
11:10 – 11:30	Small Molecule Blockade of Abeta 42 Oligomer-induced Memory Deficits
11:10 – 11:30	Susan Catalano, PhD, Cognition Therapeutics Inc.
11:30 – 11:40	Q&A
11:40 – 12:00	Screening for Inhibitors of STEP
11:40 – 12:00	Paul J. Lombroso, MD, Yale University
12:00 am – 12:10 pm	Q&A
12:10 – 12:30	Selective GABA alpha5 Ligands for Cognitive Enhancement in Patients with Mild Cognitive Impairment
12:10 – 12:30	Michela Gallagher, PhD, Johns Hopkins University
12:30 – 12:40	Q&A
12:40 – 1:45	LUNCH / VIEW POSTERS
IV. Anti-Tangles and Frontotemporal Dementia - Chair: Michael S. Wolfe, PhD, Harvard University
1:45 - 1:50	Session Overview – Michael Wolfe, PhD, Harvard University
1:50 – 2:10	Aminothienopyridazine Inhibitors of Tau Aggregation
1:50 – 2:10	Carlo Ballatore, PhD, University of Pennsylvania School of Medicine
2:10 – 2:20	Q&A
2:20 – 2:40	Targeting Tau pre-mRNA for Frontotemporal Dementia and Related Disorders
2:20 – 2:40	Michael S. Wolfe, PhD, Harvard University
2:40 – 2:50	Q&A
2:50 – 3:10	PP2A: A Novel Therapeutic Target for Alzheimer’s Disease
2:50 – 3:10	Jeffry B. Stock, PhD, Signum Biosciences
3:10 – 3:20	Q&A
3:20 – 3:50	BREAK / VIEW POSTERS
3:50 – 4:10	Immunotherapy for Clearing Pathological Tau Protein
3:50 – 4:10	Einar Sigurdsson, PhD, New York University Langone Medical Center
4:10 – 4:20	Q&A
4:20 – 4:40	Tau Clearance by Autophagy
4:20 – 4:40	Wai Haung Yu, PhD, Columbia University
4:40 – 4:50	Q&A
4:50 – 5:00	Closing Remarks
4:50 – 5:00	Howard Fillit, MD, Alzheimer's Drug Discovery Foundation